New JUPITER Analysis Demonstrates CRESTORTM (rosuvastatin) Significantly Reduces Major Cardiovascular Events in High Risk Patients
London (ots/PRNewswire) - A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50% (p=0.028; ...